Sector revisions Altimmune, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-14 EDT			5-day change	1st Jan Change
4.260 ^USD	+2.90%		-3.84%	-40.92%

07-09	Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease	CI
06-30	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility (Composite)	Nbr of analysts
	ALTIMMUNE, INC.							10
	ARGENX SE							16
	WUXI APPTEC CO., LTD.							18
	BIONTECH SE							21
	INSMED INCORPORATED							18
	SUMMIT THERAPEUTICS INC.							9
	WUXI BIOLOGICS (CAYMAN) INC.							26
	GENMAB A/S							16
	AKESO, INC.							20
	EXELIXIS, INC.							19
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							16
	VERONA PHARMA PLC							9
	LEGEND BIOTECH CORPORATION							20
	MADRIGAL PHARMACEUTICALS, INC.							14
	PHARMAESSENTIA CORPORATION							4
	SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.							2
	BIOCON LIMITED							20
	NUVALENT, INC.							10
	REMEGEN CO., LTD.							15
	Average							15
	Weighted average by Cap.							16